Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Immunohistochemical characterization of somatically derived "yolk sac tumors": analysis of a multi-institutional case series.

Created on 18 Jun 2026

Authors

Costantino Ricci, Antonio De Leo, Marco Grillini, Agnese Orsatti, João Lobo, Fernanda Fernanda-Pontes, Nuno Tiago Tavares, Joana Vieira, Francesca Ambrosi, Alessia Grillini, Eugenia Franchini, Francesco Vasuri, Sofia Nosseir, Veronica Mollica, Francesco Massari, Andres Martin Acosta, Michelangelo Fiorentino, Huili Li, Ezra Baraban

Published in

Virchows Archiv : an international journal of pathology. Jun 18, 2026. Epub Jun 18, 2026.

Abstract

A rare subset of somatic tumors shows a striking resemblance to yolk sac tumors (YSTs) of germ cell origin, including somatic carcinomas with YST/enteroblastic differentiation, fetal lung adenocarcinomas (FLACs), and YSTs in older (≥ 40 years) females. These somatic tumors express markers such as SALL4, glypican 3 (GPC 3) and alpha-fetoprotein (αFP). However, it is currently unclear to what extent they express FOXA2, HNF1β, and SOX17, which are pioneer transcription factors and key drivers of YST differentiation and stain the vast majority of chemotherapy-naïve YSTs of germ cell origin. Therefore, a multi-institutional series of seven somatically derived "YST-like" tumors was assembled and evaluated with a comprehensive panel of YST related markers (SALL4, FOXA2, HNF1β, SOX17, αFP, GATA3, and CDX2), to evaluate the potential involvement of FOXA2, HNF1β, and SOX17 in the biology of these tumors. FOXA2 and HNF1β were positive in all (7/7, 100%) YST-like tumors, followed by CDX2 (6/7, 85.7%) and SALL4 (5/7, 71.4%). In contrast, SOX17, GATA3, αFP, and GPC3 were positive in fewer cases, and showed lower percentages and intensities. Four of seven (57.1%) YST-like tumors showed synchronous/accompanying somatic neoplastic components: one clear cell carcinoma of the ovary, two urothelial carcinomas of the bladder, and one invasive non-mucinous (conventional) adenocarcinoma of the lung. HNF1β stained all these components (4/4, 100%), and all of them (4/4, 100%) stained for at least two of the YST markers evaluated (range: 2-4). In conclusion, our results support the use of an immunohistochemical panel to diagnose YST-like tumors, considering not only the most frequently expressed makers (FOXA2 and HNF1β), but also the potential expression (particularly of HNF1β) by the associated somatic neoplastic components lacking an overt YST phenotype. The consistent expression of FOXA2 and HNF1β (but not SOX17) in our cohort underscores the phenotypic overlap between YST-like tumors and YSTs of germ cell origin (type II), including shared expression of multiple pioneer transcription factors which drive the YST phenotype.

PMID:
42313184
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement